Ahmed M Soliman

7PUBLICATIONS
36CO-AUTHORS
AllergyRheumatology and arthritisPharmaceutical delivery technologiesMajor global burdens of diseaseClinical pharmacology and therapeutics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 10, 2025
Psychometric properties of the Vitiligo Noticeability Scale using data from a phase II randomized study of upadacitinib in adults with nonsegmental vitiligo.

Khaled Ezzedine, Ahmed M Soliman, Mary Kate Ladd

|Oct 01, 2025
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials.

Andrew Östör, Filip Van den Bosch, Kim Papp

|Oct 25, 2024
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis.

April W Armstrong, Ahmed M Soliman, Paolo Gisondi

|Jun 02, 2024
Health-Related Quality of Life Burden Among Adults with Vitiligo: Relationship to Disease Severity and Disease Location.

David Rosmarin, Ahmed M Soliman, James Piercy

|May 17, 2024
Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan.

Yayoi Tada, Ahmed M Soliman, Kanako Ishii

|May 10, 2024
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study.

Andreas Pinter, Ahmed M Soliman, Irina Pivneva

Pageof 2

Frequent Collaborators

3 joint publications

Heidi S Camp

2 joint publications

Khaled Ezzedine

1 joint publications

Chao Li

1 joint publications

Amit G Pandya